India’s Precision Medicine: A Vision Hindered by Biobank Regulations
Precision medicine, a transformative approach to healthcare, is redefining the landscape of disease diagnosis and treatment. From groundbreaking personalised healthcare solutions to innovations like mRNA vaccines and gene-editing technologies, the field promises a new era in medical science. Yet, as India stands on the cusp of this revolution, a significant hurdle looms: the lack of robust biobank regulations.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent analysis by The Hindu, India’s inconsistent biobank regulations threaten public trust and impede progress.
The Promise of Precision Medicine
In recent years, precision medicine has witnessed remarkable achievements. Through gene therapy, researchers have restored vision in individuals with genetic mutations, while in the U.K., scientists have reversed diabetes using reengineered stem cells. The rapid development of COVID-19 vaccines using the mRNA platform, which earned a Nobel Prize, further underscores the potential of precision medicine.
India’s Growing Market
The Indian precision medicine market is burgeoning, with projections estimating a value exceeding $5 billion by 2030. Initiatives like the BioE3 policy and the approval of NexCAR19, a domestically developed CAR-T cell therapy, mark significant strides. However, the true potential of these advancements lies in aligning biobank regulations with international standards.
The Biobank Conundrum
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the ICMR guidelines illustrate, participants often consent to provide samples without clarity on data usage, raising concerns about privacy and potential discrimination.
A Path Forward
To harness the full potential of precision medicine, India must establish stringent biobank regulations. Aligning with global standards will not only bolster public trust but also position India as a leader in next-generation therapeutics. As part of international groups like the Quad and BRICS, India has the opportunity to expand its pharmaceutical leadership and enhance its soft diplomatic efforts.
Manjeera Gowravaram, a PhD in RNA biochemistry, provides insightful analysis on the intersection of science and policy.
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
After nearly 20 years under uniquely harsh lending rules, Florida may finally see its condo market freed from a 25% down payment requirement imposed only on the state. Industry leaders say Fannie Mae could announce changes as early as December—potentially restoring the standard 10% down payment used everywhere else in the country. Experts believe the shift would boost maintenance funding, improve affordability, and stabilize Florida’s condo market after years of strain.
Phoenix’s commercial real estate market is shaking off years of uncertainty as broker optimism hits its highest level since interest rates began climbing. The latest ASU Commercial Broker Sentiment Index soared to 62.7, signaling strong confidence across multifamily, retail, office, and capital markets. With population growth accelerating, interest rates easing, and AI boosting industry efficiency, Phoenix is positioning itself for a powerful run into 2026—offering meaningful opportunities for both new and seasoned real estate professionals.
Michigan’s House Rules Committee heard testimony on a proposal that would let licensed professionals complete all required continuing education online. Supporters say the change would modernize outdated rules, reduce costs, and improve access for rural and busy workers. The state licensing department backs the measure, and lawmakers noted it could reshape CE options across industries from real estate to insurance and healthcare.
Florida homeowners are now paying an average of $5,838 per year for insurance — nearly $3,000 above the national average — making it one of the most expensive states in the country. As premiums continue to triple for some residents, many are being forced into tough decisions, from delaying home improvements to dropping coverage altogether. With more than 40% of claims closed with no payment and lawmakers pushing for aggressive reforms, the crisis is reshaping Florida’s housing market and placing growing pressure on real estate, mortgage, and insurance professionals statewide.
Griffin Funding has elevated John Jones to Senior Vice President of Growth and EOS Integrator, marking a major step in the company’s long-term expansion strategy. Already a key operational leader since April 2025, Jones will now drive performance optimization, market expansion, and leadership development as the lender pursues an ambitious goal of reaching $3 billion in annual non-QM loan volume by 2030. His promotion underscores Griffin Funding’s commitment to scaling strategically while strengthening its position in the fast-growing non-QM space.
Despite recent Federal Reserve rate cuts, commercial real estate remains frozen. Long‑term Treasury yields continue to climb, keeping borrowing costs high and preventing the relief investors expected. With nearly $1 trillion in commercial loans coming due, refinancing at today’s elevated rates is squeezing owners, slowing transactions, and creating a widening gap between buyers and sellers. For patient, well‑capitalized investors, this period of recalibration may offer some of the strongest opportunities in years.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent 
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the 
